Adenosine Triphosphate
CAS 56-65-5
Adenosine Triphosphate (CAS 56-65-5) is a Phase 2 pharmaceutical compound with 21 bioactivity targets and 125 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 14298.530882352941 nM | 68 | - |
| - | EC50 | 4843.709090909091 nM | 55 | - |
| - | IC50 | 24252.308 nM | 14 | - |
| - | Kd | 2270 nM | 9 | - |
| - | Potency | 17436.420000000002 nM | 5 | - |
| - | Ki | 45009 nM | 2 | - |
| P2Y purinoceptor 1 GPCR |
EC50 | 5.55 | - | Meleagris gallopavo |
| P2X purinoceptor 1 Ion channel |
EC50 | 7.25 | - | Homo sapiens |
| P2Y purinoceptor 4 GPCR |
Ki | 6.2 | - | Homo sapiens |
| Tyrosine-protein kinase JAK2 Kinase |
Kd | 5.89 | - | Homo sapiens |
| P2Y purinoceptor 1 GPCR |
EC50 | 6.07 | - | Homo sapiens |
| P2Y purinoceptor 2 GPCR |
EC50 | 7.1 | - | Homo sapiens |
| P2Y purinoceptor 11 GPCR |
EC50 | 5.17 | - | Homo sapiens |
| Transient receptor potential cation channel subfamily M member 4 Ion channel |
IC50 | 5.8 | - | Homo sapiens |
| P2Y purinoceptor 13 GPCR |
IC50 | 5.4 | - | Homo sapiens |
| Endoplasmin Membrane other |
IC50 | 5.49 | - | Canis familiaris |
| MAP kinase-activated protein kinase 2 Kinase |
IC50 | 5.55 | - | Homo sapiens |
| Mitogen-activated protein kinase kinase kinase 7 Kinase |
Kd | 5.55 | - | Homo sapiens |
| P2X purinoceptor 4 Ion channel |
EC50 | 6.3 | - | Homo sapiens |
| Uracil nucleotide/cysteinyl leukotriene receptor GPCR |
EC50 | 7.43 | - | Homo sapiens |
| P2X purinoceptor 3 Ion channel |
Ki | 7.836 | - | Homo sapiens |
| Heat shock protein 75 kDa, mitochondrial Unclassified |
IC50 | 4.5 | - | Homo sapiens |
| Adenylate kinase 2 Kinase |
Ki | 4.05 | - | Rattus norvegicus |
| Heat shock cognate 71 kDa protein Unclassified |
IC50 | 4.76 | - | Homo sapiens |
| Heat shock 70 kDa protein 1A Unclassified |
IC50 | 5.47 | - | Homo sapiens |
| Transient receptor potential cation channel subfamily M member 4 Ion channel |
IC50 | 6.1 | - | Mus musculus |
| P2X purinoceptor 2 Ion channel |
EC50 | 5.85 | - | Rattus norvegicus |
| P2X purinoceptor 4 Ion channel |
EC50 | 6 | - | Mus musculus |
| P2Y purinoceptor 4 GPCR |
EC50 | 6.3 | - | Rattus norvegicus |
| P2X purinoceptor 4 Ion channel |
EC50 | 5.3 | - | Rattus norvegicus |
| P2X purinoceptor 6 Ion channel |
EC50 | 6 | - | Rattus norvegicus |
| P2X purinoceptor 5 Ion channel |
EC50 | 6 | - | Rattus norvegicus |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Sudden hearing loss | 8 | 44.21 | 10061373 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| GPR17 GPR17 |
Agonist | 7.43 pEC50 | 21773766 |
| IP 3 R1 ITPR1 |
Activator | - | - |
| K Na 1.2 Kcnt2 |
Gating inhibitor | - | 14684870 |
| K ir 6.1 Kcnj8 |
Agonist | - | 9130167 |
| K ir 6.1 Kcnj8 |
Antagonist | - | 9130167 |
| K ir 6.2 Kcnj11 |
Antagonist | - | 7502040|8630239 |
| P2X1 P2RX1 |
Agonist | 7.25 pEC50 | 12213051 |
| P2X2 P2rx2 |
Agonist | 5.849999904632568 pEC50 | 18600475 |
| P2X3 P2RX3 |
Agonist | 6.46999979019165 pEC50 | 12213051 |
| P2X4 P2rx4 |
Agonist | 5.300000190734863 pEC50 | 10694247 |
| P2X4 P2RX4 |
Agonist | 5.900000095367432 pEC50 | 10694247 |
| P2X4 P2rx4 |
Agonist | 6.0 pEC50 | 12213051 |
| P2X4 P2rx4 |
Agonist | 5.599999904632568 pEC50 | 10694247 |
| P2X4 P2RX4 |
Agonist | 6.300000190734863 pEC50 | 12213051 |
| P2X5 P2rx5 |
Agonist | 6.0 pEC50 | 12213051 |
| P2X6 P2rx6 |
Agonist | 6.0 pEC50 | 12213051 |
| P2X7 P2RX7 |
Agonist | 3.109999895095825 pEC50 | 12213051 |
| P2Y 1 receptor P2RY1 |
Partial agonist | 6.099999904632568 pIC50 | 9154346|12391289 |
| P2Y 1 receptor P2RY1 |
Antagonist | 4.8 pKi | 9547364 |
| P2Y 11 receptor P2RY11 |
Full agonist | 4.199999809265137 pEC50 | 10578132|12761346|12213051 |
| P2Y 13 receptor P2RY13 |
Full agonist | 5.4 pIC50 | 12815166 |
| P2Y 2 receptor P2RY2 |
Full agonist | 6.639999866485596 pEC50 | 8564228|11754592|12213051 |
| P2Y 4 receptor P2RY4 |
Agonist | 5.369999885559082 pEC50 | 12213051 |
| P2Y 4 receptor P2ry4 |
Partial agonist | 5.699999809265137 pEC50 | 9647463|10779375|12213051 |
| P2Y 4 receptor P2RY4 |
Antagonist | 6.199999809265137 pKd | 10779375 |
| RyR1 RYR1 |
Activator | - | - |
| RyR2 RYR2 |
Activator | - | - |
| RyR3 RYR3 |
Activator | - | - |
| TRPM4 Trpm4 |
Antagonist | 6.1 pIC50 | 15670874 |
| TRPM4 TRPM4 |
Antagonist | 5.8 pIC50 | 14758478 |
| TRPM4 TRPM4 |
Antagonist | 4.9 pIC50 | 14758478 |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| adenosine triphosphate | 318 | IN | RXNORM |
| ATP | 318 | SY | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Adenosine Triphosphate used for in pharmaceutical contexts?
Adenosine Triphosphate (CAS 56-65-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Adenosine Triphosphate?
Adenosine Triphosphate has 125 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Sudden hearing loss, Abdominal discomfort, Abdominal pain upper, Acute myocardial infarction, Adrenal gland cancer. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Adenosine Triphosphate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Adenosine Triphosphate (ATP) with EU status "permitted".
What clinical phase is Adenosine Triphosphate in?
Adenosine Triphosphate is rendered with ChEMBL max phase 2.
What bioactivity targets are documented for Adenosine Triphosphate?
Adenosine Triphosphate has 32 bioactivity rows in this page query. Rendered target entries include P2Y purinoceptor 1, P2X purinoceptor 1, P2Y purinoceptor 4, Tyrosine-protein kinase JAK2, P2Y purinoceptor 2.